0.51(1.85%) Volume: 85,673 10:09PM EST| Market Cap : 1.38 B | Enterprise Value : 1.21 B | P/E (TTM) : | P/B : 7.15 |
|---|
NAS:ZLAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ZLAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 235.07 |
ZLAB's Cash-to-Debt is ranked higher than
61% of the 1078 Companies in the Global Biotechnology industry. ( Industry Median: 64.02 vs. ZLAB: 235.07 ) Ranked among companies with meaningful Cash-to-Debt only. |
ZLAB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 235.07 Med: No Debt Max: No Debt Current: 235.07 |
| Debt-to-EBITDA | -0.01 |
ZLAB's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 2.04 vs. ZLAB: -0.01 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
ZLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.01 Med: 0 Max: 0 Current: -0.01 |
| Interest Coverage | No Debt |
ZLAB's Interest Coverage is ranked higher than
52% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. ZLAB: No Debt ) Ranked among companies with meaningful Interest Coverage only. |
ZLAB'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt Current: No Debt |
| Piotroski F-Score: 5 |
|
| Altman Z-Score: 55.66 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| ROE % | -55.76 |
ZLAB's ROE % is ranked lower than
82% of the 989 Companies in the Global Biotechnology industry. ( Industry Median: -42.82 vs. ZLAB: -55.76 ) Ranked among companies with meaningful ROE % only. |
ZLAB'
s ROE % Range Over the Past 10 Years
Min: -55.76 Med: 0 Max: 0 Current: -55.76 |
| ROA % | -35.86 |
ZLAB's ROA % is ranked higher than
50% of the 1084 Companies in the Global Biotechnology industry. ( Industry Median: -34.77 vs. ZLAB: -35.86 ) Ranked among companies with meaningful ROA % only. |
ZLAB'
s ROA % Range Over the Past 10 Years
Min: -129.28 Med: -101.12 Max: -35.86 Current: -35.86 |
| ROC (Joel Greenblatt) % | -527.62 |
ZLAB's ROC (Joel Greenblatt) % is ranked lower than
55% of the 1036 Companies in the Global Biotechnology industry. ( Industry Median: -521.46 vs. ZLAB: -527.62 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
ZLAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3943.6 Med: -3126.39 Max: -527.62 Current: -527.62 |
| George Soros 17,500 sh (New) Steven Cohen 50,000 sh (New) Ron Baron 1,900,431 sh (+1955.83%) |
| Jim Simons 22,000 sh (New) Ron Baron 1,974,013 sh (+3.87%) | Steven Cohen Sold Out George Soros Sold Out |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | ROCO:4174, XMCE:ROVI, NAS:MGNX, OCSE:BAVA, SHSE:603566, SZSE:002022, XKRX:078160, NAS:NTLA, SHSE:603718, XKRX:003000, SZSE:002872, NAS:BOLD, NAS:ACOR, NAS:ADAP, NAS:RVNC, SZSE:300149, SAU:2070, SHSE:600200, OSTO:HMED, TSXV:CRON » details | |
| Traded in other countries: | 1ZL.Germany, | |
| Headquarter Location: | China |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 7.15 |
ZLAB's PB Ratio is ranked lower than
54% of the 962 Companies in the Global Biotechnology industry. ( Industry Median: 4.10 vs. ZLAB: 7.15 ) Ranked among companies with meaningful PB Ratio only. |
ZLAB'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 8.15 Current: 7.15 |
| EV-to-EBIT | -23.48 |
ZLAB's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies in the Global Biotechnology industry. ( Industry Median: 22.17 vs. ZLAB: -23.48 ) Ranked among companies with meaningful EV-to-EBIT only. |
ZLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -27.32 Med: 0 Max: 0 Current: -23.48 |
| EV-to-EBITDA | -23.72 |
ZLAB's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies in the Global Biotechnology industry. ( Industry Median: 18.08 vs. ZLAB: -23.72 ) Ranked among companies with meaningful EV-to-EBITDA only. |
ZLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.62 Med: 0 Max: 0 Current: -23.72 |
| Current Ratio | 17.78 |
ZLAB's Current Ratio is ranked higher than
90% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.46 vs. ZLAB: 17.78 ) Ranked among companies with meaningful Current Ratio only. |
ZLAB'
s Current Ratio Range Over the Past 10 Years
Min: 3.36 Med: 16.26 Max: 19.11 Current: 17.78 |
| Quick Ratio | 17.78 |
ZLAB's Quick Ratio is ranked higher than
91% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. ZLAB: 17.78 ) Ranked among companies with meaningful Quick Ratio only. |
ZLAB'
s Quick Ratio Range Over the Past 10 Years
Min: 3.36 Med: 16.26 Max: 19.11 Current: 17.78 |
| vs
industry |
vs
history |
|---|
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Net-Cash | 8.55 |
ZLAB's Price-to-Net-Cash is ranked higher than
63% of the 613 Companies in the Global Biotechnology industry. ( Industry Median: 7.29 vs. ZLAB: 8.55 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
ZLAB'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.93 Med: 6.01 Max: 9.03 Current: 8.55 |
| Price-to-Net-Current-Asset-Value | 8.32 |
ZLAB's Price-to-Net-Current-Asset-Value is ranked higher than
61% of the 745 Companies in the Global Biotechnology industry. ( Industry Median: 6.45 vs. ZLAB: 8.32 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
ZLAB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.9 Med: 5.9 Max: 8.79 Current: 8.32 |
| Price-to-Tangible-Book | 7.14 |
ZLAB's Price-to-Tangible-Book is ranked higher than
54% of the 894 Companies in the Global Biotechnology industry. ( Industry Median: 5.32 vs. ZLAB: 7.14 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
ZLAB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.51 Med: 5.21 Max: 7.54 Current: 7.14 |
| Earnings Yield (Greenblatt) % | -4.26 |
ZLAB's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1081 Companies in the Global Biotechnology industry. ( Industry Median: -7.73 vs. ZLAB: -4.26 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
ZLAB'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.54 Med: 0 Max: 0 Current: -4.26 |
| EPS (TTM) $ | -1.35 |
|---|---|
| Volatility | 53.57% |
| 52-Week Range $ | 14.29 - 33.86 |
| Shares Outstanding (Mil) | 50.61 |
| Dec18 | Dec19 | Dec20 | |
|---|---|---|---|
| Revenue (Mil $) | 17 | 49 | |
| EBIT (Mil $) | -55 | -62 | -66 |
| EBITDA (Mil $) | -53 | -58 | -60 |
| EPS ($) | -0.96 | -0.96 | -1.05 |
| EPS without NRI ($) | -0.96 | -0.96 | -1.05 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
| Dividends per Share ($) | |||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP